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1. INTRODUCTION {#prp2477-sec-0001}
===============

One of the most potent mediators of angiogenesis is vascular endothelial growth factor (VEGF).[1](#prp2477-bib-0001){ref-type="ref"}, [2](#prp2477-bib-0002){ref-type="ref"} The VEGF family of dimeric polypeptide ligands includes VEGF‐A, VEGF‐B, VEGF‐C, VEGF‐D, placental growth factor (PlGF), the virus‐encoded VEGF‐E, and the snake venom‐derived VEGF‐F.[2](#prp2477-bib-0002){ref-type="ref"} VEGF‐A has been identified as the key regulator of angiogenesis, a process critical for tumor progression.[3](#prp2477-bib-0003){ref-type="ref"}, [4](#prp2477-bib-0004){ref-type="ref"} As a result, several antiangiogenic therapeutics aimed at targeting VEGF, or its receptors, have emerged as key adjuvant cancer treatments in the prolongation of progression‐free survival and, in some cases, overall survival.[1](#prp2477-bib-0001){ref-type="ref"}

A number of receptor tyrosine kinase inhibitors (RTKIs) that target VEGFR2 [5](#prp2477-bib-0005){ref-type="ref"}, [6](#prp2477-bib-0006){ref-type="ref"} are now routinely used in the treatment of advanced stage, or metastatic disease.[1](#prp2477-bib-0001){ref-type="ref"}, [6](#prp2477-bib-0006){ref-type="ref"}, [7](#prp2477-bib-0007){ref-type="ref"} Vandetanib (Caprelsa^®^) and pazopanib (Votrient^®^) are used to treat medullary thyroid cancer and advanced renal cell carcinoma, respectively.[8](#prp2477-bib-0008){ref-type="ref"}, [9](#prp2477-bib-0009){ref-type="ref"} Furthermore, sunitinib (Sutent^®^) is used for the treatment of renal cell carcinoma, gastrointestinal stromal tumors and pancreatic neuroendocrine tumors, while sorafenib (Nexavar ^®^) is indicated for late‐stage treatment of hepatocellular carcinoma or advanced metastatic renal cell carcinoma.[10](#prp2477-bib-0010){ref-type="ref"}, [11](#prp2477-bib-0011){ref-type="ref"}

RTKIs that inhibit VEGFR2 tyrosine kinase activity effectively reduce angiogenesis, potentially by decreasing the number of vessel nodes and vessel length in a tumor.[1](#prp2477-bib-0001){ref-type="ref"}, [4](#prp2477-bib-0004){ref-type="ref"}, [7](#prp2477-bib-0007){ref-type="ref"} Over time, this induces a hypoxic environment within the tumor that leads to tumor cell death and a reduction in tumor size.[12](#prp2477-bib-0012){ref-type="ref"} Since these anticancer therapies target the tumor microvascular environment, it is perhaps not surprising that significant cardiovascular side effects have been reported, both clinically and in preclinical studies.[13](#prp2477-bib-0013){ref-type="ref"}, [14](#prp2477-bib-0014){ref-type="ref"} For example, in patients treated with bevacizumab, a humanized monoclonal antibody that targets the VEGF‐A ligand, 28% of patients developed Grade 3 hypertension (\>180 mm Hg systolic pressure).[15](#prp2477-bib-0015){ref-type="ref"} This pressor effect is also observed with small molecules that inhibit VEGFR2 signaling.[15](#prp2477-bib-0015){ref-type="ref"} Thus, 15%‐60% of patients treated with small molecule RTKIs have been reported to be associated with an increased incidence of hypertension.[16](#prp2477-bib-0016){ref-type="ref"} Furthermore, the escalation of hypertension in these patients is linked with severe cardiovascular complications such as thromboembolism, intracerebral hemorrhage, stroke, and myocardial infarction, often resulting in termination of treatment.[13](#prp2477-bib-0013){ref-type="ref"} Vandetanib has been shown to cause ECG prolongation, and hypertension in over 32% of patients, with 9% of those treated with vandetanib developing Grade 3 hypertension.[17](#prp2477-bib-0017){ref-type="ref"} Similarly, hypertension occurs in approximately 40%‐57% of patients treated with pazopanib, with 3% of those developing Grade 3 hypertension.[18](#prp2477-bib-0018){ref-type="ref"}, [19](#prp2477-bib-0019){ref-type="ref"} For most patients, the onset of hypertension occurs within 4 weeks of treatment.[18](#prp2477-bib-0018){ref-type="ref"}, [19](#prp2477-bib-0019){ref-type="ref"}

We recently recapitulated the hypertensive effects of a number of RTKIs that target VEGFR2[5](#prp2477-bib-0005){ref-type="ref"} in a conscious rat model[20](#prp2477-bib-0020){ref-type="ref"} in which the regional hemodynamic effects of four RTKIs (including pazopanib and vandetanib) were monitored over a period of 4 days. This study showed that RTKIs consistently caused hypertension, which was associated with regionally selective vasoconstrictions, particularly in the hindquarters and mesenteric vascular beds.[20](#prp2477-bib-0020){ref-type="ref"} Short‐term radiotelemetric studies in rats have also examined the effects of RTKIs on blood pressure and heart rate (HR). Isobe et al[21](#prp2477-bib-0021){ref-type="ref"} dosed animals over four consecutive days with vehicle, cediranib (0.1‐10 mg/kg), sunitinib (0.5‐40 mg/kg), or sorafenib (0.1‐5 mg/kg).[21](#prp2477-bib-0021){ref-type="ref"} The study clearly demonstrated significantly elevated blood pressures within a few days of the initiation of dosing with RTKIs. Similarly, Lankhorst et al[22](#prp2477-bib-0022){ref-type="ref"} showed a dose‐dependent elevation in mean arterial pressure (MAP) following administration of sunitinib (7‐26.7 mg/day) over a period of 5 days.[22](#prp2477-bib-0022){ref-type="ref"} More recently Collins et al[23](#prp2477-bib-0023){ref-type="ref"} evaluated more selected kinase inhibitors with VEGFR‐2 activity, AZ1, and regorafenib, again showing pressor effects when treatment was continued over a period of 4 days.[23](#prp2477-bib-0023){ref-type="ref"}

In the present study, we have used radiotelemetry to evaluate the longer‐term impact of prolonged RTKI treatment on the cardiovascular system, with particular attention given to the extent to which hypertension is sustained, both during and after cessation of treatment. To this end, we have evaluated the cardiovascular effects of two clinically available RTKIs, vandetanib, and pazopanib, over a 21‐day dosing "on"‐period and during a 10‐day post "off"‐treatment period, in freely moving, telemetered rats.

2. MATERIALS AND METHODS {#prp2477-sec-0002}
========================

2.1. Animals {#prp2477-sec-0003}
------------

Adult, male, Sprague‐Dawley rats (Charles River Laboratories, UK) weighing 300‐400 g were housed in groups in a temperature‐controlled (21‐23°C) environment with a 12 hours light--dark cycle (lights on at 06:00) and free access to food (18% Protein Rodent Diet; Teklad Global, Bicester, United Kingdom) and water ad libitum. Following surgery, telemetered rats were pair‐housed in standard individually ventilated cages, placed upon single DSI receivers, with a noninstrumented companion rat throughout the duration of the study. Cages were prepared with bedding material and enrichment. All procedures were carried out with approval of the University of Nottingham Animal Welfare Ethical Review Board under Home Office Project and Personal License Authority. Every effort was made to ensure that animals experienced minimal discomfort. Twenty‐two rats were used for this study, and results are recorded in accordance with the ARRIVE guidelines for reporting experiments involving animals.[24](#prp2477-bib-0024){ref-type="ref"}

2.2. Surgical implantation of radiotelemetric devices {#prp2477-sec-0004}
-----------------------------------------------------

Surgery was performed under general anesthesia (fentanyl citrate and medetomidine, 300 μg/kg each, i.p., supplemented as required). Sprague Dawely rats were implanted with telemetry transmitters, DSI C50PXT (Study 1: vandetanib), and DSI HDS11 (Study 2: pazopanib) (Data Sciences International, St. Paul, MN USA). For both devices, the catheter tip was advanced via the distal abdominal aorta until approximately 1 cm below the renal artery, as described previously.[25](#prp2477-bib-0025){ref-type="ref"} The positive ECG lead was secured to the xiphoid sternum and the negative ECG lead was placed over the manubrium and tunneled subcutaneously from the abdomen to the anterior of the neck.[26](#prp2477-bib-0026){ref-type="ref"} The telemetry device was secured to the body wall. Following surgery, the animals received reversal of anesthesia and postoperative analgesia provided by atipamezole hydrochloride (1 mg/kg, s.c.) and buprenorphine (0.02 mg/kg, s.c.). A second dose of buprenorphine (0.02 mg/kg, i.p.) was given as an analgesic 4 hours after surgery and a daily dose of buprenorphine (30 mg/kg, s.c.) and carprofen (0.5%) was administered for 4 days postsurgery. The animals were recovered for at least 10 days, and after a satisfactory inspection from the Named Veterinary Surgeon the animals were randomized to either a vehicle or treatment group. At the end of each experiment, rats were euthanized via a schedule 1 method, with Euthatal (60‐80 mg, i.p.) and exsanguination.

2.3. Telemetry {#prp2477-sec-0005}
--------------

Following recovery from surgery, radiotelemetry devices were switched on and baseline recordings of HR, mean systolic blood pressure (SBP), mean diastolic blood pressure (DBP), and mean arterial blood pressure (MAP) were recorded every 15 minutes for a period of 1 min throughout the experimental period (approximately 35 days in total). Baseline recordings were collected for a minimum of 4 days prior to the start of treatment. After this baseline monitoring period, rats were randomly assigned into two studies:

*Study 1:* Rats were randomly administered vehicle (volume 0.5 mL; n = 5) or vandetanib 25 mg/kg/day (volume 0.5 mL; n = 6), dosed i.p, once every 24 hours for 21 days. All solutions were prepared in (2% Tween, 5% propylene glycol in 0.9% saline solution).

*Study 2:* Animals were randomly assigned to receive vehicle (volume 0.5 mL; n = 4) or pazopanib 30 mg/kg/day (volume 0.5 mL; n = 7), dosed i.p, once every 24 hours for 21 days. All solutions were prepared in (2% Tween, 5% propylene glycol in 0.9% saline solution).

2.4. Drugs, chemical reagents, and other materials {#prp2477-sec-0006}
--------------------------------------------------

Pazopanib and vandetanib were purchased from Sequoia Research Products, UK. Fentanyl citrate was purchased from Jansen‐Cilac Ltd, UK. Medetomidine (Domitor), carprofen (Rimadyl) and atipamezole hydrochloride (Antisedan) were purchased from Pfizer, UK. Buprenorphine (Vetergesic) and pentobarbitone (Euthatal) were purchased from Alstoe Animal Health, UK. Tween and propylene glycol were purchased from Sigma‐Aldrich, UK.

2.5. Data analysis {#prp2477-sec-0007}
------------------

Twenty‐four hours (00:00‐23:45), morning (06:00‐12:00) and evening (18:00‐23:45) recording averages (means) were calculated to give HR, MAP, SBP, and DBP values. Change from baseline calculations (time point ‐ average of the baseline = change from baseline) were used to determine ΔHR, ΔMAP, ΔSBP, and ΔDBP.

To evaluate vandetanib‐ or pazopanib‐induced changes in circadian cycling during initial 2 days of dosing and the last 2 days of dosing followed by the 10‐day postdosing period with vandetanib and pazopanib, each 24 hours day was divided into 6, 3 hours bins (06:00‐09:00, 09:00‐12:00, 12:00‐15:00, 15:00‐18:00, 18:00‐21:00, and 21:00‐24:00) and HR, MAP, SBP, and DBP were calculated for: (1) the last 2 days of baseline (pre‐treatment) and the first 3 days of dosing with either vandetanib, pazopanib, or vehicle; (2) days 20 and 21 of dosing with vandetanib, pazopanib, or vehicle, followed by the 10‐day "off"‐treatment period (days 22‐31).

All data were expressed as mean ± SEM. Data were analyzed using Prism 6 software (GraphPad software, USA). Differences were considered significant if the *P*‐value was less than 0.05. To assess statistical differences between vehicle or treatment groups (vandetanib or pazopanib), two‐tailed comparisons of the integrated area under the curve were made using the Mann‐Whitney‐U test. A repeated measures ANOVA with Sidak\'s correction was used to compare drug treatment to vehicle at individual time points. A repeated measures nonparametric ANOVA with Dunnet\'s correction was used to compare each time point to the baseline average.

3. RESULTS {#prp2477-sec-0008}
==========

In the present study, we investigated hemodynamic responses to vandetanib (25 mg/kg/day, i.p.) or pazopanib (30 mg/kg/day, i.p.) in conscious telemetered rats following chronic treatment, over a 21‐day dosing period and a 10‐day "off"‐treatment period. The circadian rhythm, oscillating cycles of cardiovascular variables over a 24 hours time period, were also measured during the last 2 days of baseline followed by the first 3 days of dosing with vandetanib, pazopanib, or vehicle and the last 2 days of dosing followed by the 10‐day posttreatment period. This was to investigate whether vandetanib or pazopanib interfered with the natural cycling of hemodynamic processes over a 24 hours period and over multiple days. Baseline cardiovascular variables before the administration of RTKI or the corresponding vehicle are shown in Table [1](#prp2477-tbl-0001){ref-type="table"}.

###### 

Baseline cardiovascular variables for heart rate (HR), mean arterial pressure (MAP), systolic blood pressure (SBP), and DBP (24 h). Statistics: \**P* \< 0.05; Comparing vehicle and vandetanib groups or vehicle and pazopanib groups. Values have been rounded to the nearest whole number

                                    HR (beats/min)   MAP (mm Hg)   SBP (mm Hg)   DBP (mm Hg)
  --------------------------------- ---------------- ------------- ------------- -------------
  Series 1 baseline values                                                       
  Vehicle 1 (n = 5)                 395 ± 2          108 ± 0       128 ± 0       92 ± 0
  Vandetanib 25 mg/kg/day (n = 6)   373 ± 4\*        108 ± 0       128 ± 0       92 ± 1
  Series 2 baseline values                                                       
  Vehicle 2 (n = 4)                 370 ± 5          101 ± 0       124 ± 0       83 ± 0
  Pazopanib 30 mg/kg/day (n = 7)    372 ± 4          99 ± 0        120 ± 0\*     82 ± 0

John Wiley & Sons, Ltd

3.1. Cardiovascular effects of Vandetanib {#prp2477-sec-0009}
-----------------------------------------

### 3.1.1. Heart rate {#prp2477-sec-0010}

A single, daily dose of vandetanib for 21 days did not significantly alter HR compared to baseline at any time point during either the dosing period or the "off"‐treatment period (Figure S1a,c,e). Vandetanib did, however, significantly decrease the change in HR (ΔHR; relative to the corresponding initial baseline measurement obtained for each animal) on the 4th and 10th day of dosing and the 2nd, 6th, and 10th day of the "off"‐treatment period (Figure S1b). The majority of these ΔHR decreases appeared during the animal\'s active phase (21:00‐06:00) for both the dosing and the posttreatment periods (Figure S1d). However, declines in HR and ΔHR over time were also found with vehicle (Figures S1a‐f) suggesting that the changes in HR from the initial baseline measurements were probably not entirely due to vandetanib. This is probably a consequence of habituation to the dosing regimens and a reduction in sympathetic nervous system activity.

When integrated area under the curve analysis was undertaken, it identified significant differences between the vandetanib and vehicle groups for the duration of the 21‐day dosing period and the 10‐day posttreatment period (Mann‐Whitney U test, \# = *P* \< 0.05; Figure S1d‐f). Vandetanib did not significantly alter the circadian rhythm of HR compared to baseline during the initial 3 days of dosing (Figure [1](#prp2477-fig-0001){ref-type="fig"}A) or the last 2 days of dosing followed by the 10‐day posttreatment period (Figure [1](#prp2477-fig-0001){ref-type="fig"}B). Integrated area under the curve analysis of these data detected significant differences between vehicle and vandetanib during the initial 3 days of dosing and the 10‐day posttreatment period (Figures [1](#prp2477-fig-0001){ref-type="fig"}A‐B). Thus, the peak‐trough amplitude of the circadian rhythm in HR decreased during the first 3 days of treatment with vandetanib (Figure [1](#prp2477-fig-0001){ref-type="fig"}A) and then recovered during the "off"‐treatment period (Figure [1](#prp2477-fig-0001){ref-type="fig"}B). Bradycardic tendencies were also observed during the days 1‐5 and 5‐10 averages, of the "off"‐treatment period (Table S1).

![Circadian oscillations of the mean heart rate (HR) of rats dosed with vandetanib 25 mg/kg/day (n = 6) and vehicle (n = 5). During: (A) 2 days prior to dosing followed by the first 3 days of dosing; and (B) the last 2 days of the dosing period followed by 10 days "off‐treatment". Data are displayed as mean ± SEM. \**P* \< 0.05 comparing each time point to baseline; ^+^ *P* \< 0.05 comparing vehicle vs vandetanib at the same time point and ^\#^ *P* \< 0.05 comparing area over or under the curve of vehicle vs vandetanib](PRP2-7-e00477-g001){#prp2477-fig-0001}

### 3.1.2. Blood pressure {#prp2477-sec-0011}

Significant pressor effects of vandetanib (*P* \< 0.05) were observed on both MAP (Figure [2](#prp2477-fig-0002){ref-type="fig"}A,C,E) and the change in MAP from the original baseline measurement of each individual animal (ΔMAP) (Figure [2](#prp2477-fig-0002){ref-type="fig"}B,D,F). There was a significant increase in ΔMAP compared to baseline from the first active evening phase of vandetanib dosing and this elevation remained throughout the 21‐day dosing period and 6 days into the "off"‐treatment period (Figure [2](#prp2477-fig-0002){ref-type="fig"}B,D,F). The maximum response was achieved on the 20th day of treatment (24 hours measurement; vandetanib = +13 ± 2 mm Hg, vehicle = +1 ± 1 mm Hg, *P* \< 0.05; Figure [2](#prp2477-fig-0002){ref-type="fig"}A). Over the 24 hours recording period, ΔMAP appeared to have a sustained component during the "off"‐treatment period (Figure [2](#prp2477-fig-0002){ref-type="fig"}B). This was particularly apparent during the resting morning recordings (06:00‐12:00) (Figure [2](#prp2477-fig-0002){ref-type="fig"}D). Consistent and significant differences in both MAP and ΔMAP were observed between vehicle and vandetanib throughout the 21‐day dosing period and during the 10‐day "off"‐treatment period (Mann‐Whitney U test, *P* \< 0.05; Figure [2](#prp2477-fig-0002){ref-type="fig"}A‐F). MAP elevations were also sustained throughout the 10‐day "off"‐treatment period, and this was significant compared to vehicle, during days 1‐5 and 5‐10 (Table S1). There was no evidence of tolerance to the effects of vandetanib, at least in terms of blood pressure responses, during the 21‐day treatment period (Figure [2](#prp2477-fig-0002){ref-type="fig"}A‐F).

![Mean arterial blood pressure (MAP) of rats dosed with vandetanib 25 mg/kg/day (n = 6) and vehicle (n = 5). A, MAP and B, change in MAP compared to baseline (ΔMAP) measured for 24 hours; C, MAP and D, ΔMAP measured during the morning (06:00‐12:00); E, MAP and F, ΔMAP measured during the evening (18:00‐23:45). Data are displayed as mean ± SEM. \**P* \< 0.05 comparing each time point to baseline; ^+^ *P* \< 0.05 comparing vehicle vs vandetanib at the same time point and ^\#^ *P* \< 0.05 comparing area over or under the curve of vehicle vs vandetanib](PRP2-7-e00477-g002){#prp2477-fig-0002}

Vandetanib significantly (*P* \< 0.05) increased SBP and the change in SBP from baseline (ΔSBP) from the second day of dosing (Figure [3](#prp2477-fig-0003){ref-type="fig"}A‐F). Vandetanib caused significant increases in ΔSBP compared to vehicle and this elevation appeared to be of a larger magnitude during the morning resting phase (Figure [3](#prp2477-fig-0003){ref-type="fig"}D). Significant increases in SBP were also found with vandetanib treatment compared to vehicle for the entire 10‐day "off"‐treatment period (Figure [3](#prp2477-fig-0003){ref-type="fig"}A‐F; Table S1). Vandetanib induced smaller increases in mean DBP and change in DBP from baseline (ΔDBP) that is probably not physiologically relevant (Figure [4](#prp2477-fig-0004){ref-type="fig"}A‐F; Table S1).

![Mean systolic pressure (SBP) of rats dosed with vandetanib 25 mg/kg/day (n = 6) and vehicle (n = 5). A, SBP and B, change in SBP compared to baseline (ΔSBP) measured for 24 hours; C, SBP and D, ΔSBP measured during the morning (06:00‐12:00); E, SBP and F, ΔSBP during the evening (18:00‐23:45). Data displayed as mean ± SEM. \**P* \< 0.05 comparing each time point to baseline; ^+^ *P* \< 0.05 comparing vehicle vs vandetanib at the same time point and ^\#^ *P* \< 0.05 comparing area over or under the curve of vehicle vs vandetanib](PRP2-7-e00477-g003){#prp2477-fig-0003}

![Mean diastolic pressure (DBP) of rats dosed with vandetanib 25 mg/kg/day (n = 6) and vehicle (n = 5). A, DBP and B, change in DBP compared to baseline (ΔDBP) measured for 24 h; C, DBP and D, ΔDBP measured during the morning (06:00‐12:00); E, DBP and F, ΔDBP measured during the evening (18:00‐23:45). Data are displayed as mean ± SEM. \**P* \< 0.05 comparing each time point to baseline; ^+^ *P* \< 0.05 comparing vehicle vs vandetanib at the same time point and ^\#^ *P* \< 0.05 comparing area over or under the curve of vehicle vs vandetanib](PRP2-7-e00477-g004){#prp2477-fig-0004}

Circadian rhythm observations revealed that MAP, SBP, and DBP levels peaked during rodent active evening phase and reached lower levels during the rodent resting phase throughout the baseline and posttreatment periods. During the vandetanib dosing period, these oscillations were disturbed and clear elevations in all three pressure responses were observed (Figure [5](#prp2477-fig-0005){ref-type="fig"}A‐F). This contrasted with the better maintained circadian rhythm observed in HR (Figure [1](#prp2477-fig-0001){ref-type="fig"}A‐B).

![Circadian oscillations of: (A‐B) mean arterial pressure (MAP), (C‐D) systolic blood pressure (SBP), and (E‐F) diastolic blood pressure (DBP) in rats dosed with vandetanib 25 mg/kg/day (n = 6) and vehicle (n = 5). Representing: (A, C, E) 2 days prior to dosing; and the first 3 days of dosing; and (B, D, F) the last 2 days of dosing followed by 10 days "off‐treatment". Data are displayed as mean ± SEM. \**P* \< 0.05 comparing each time point to baseline; ^+^ *P* \< 0.05 comparing vehicle vs vandetanib at the same time point and ^\#^ *P* \< 0.05 comparing area over or under the curve of vehicle vs vandetanib](PRP2-7-e00477-g005){#prp2477-fig-0005}

3.2. Cardiovascular effects of Pazopanib {#prp2477-sec-0012}
----------------------------------------

### 3.2.1. Heart rate {#prp2477-sec-0013}

Pazopanib did not significantly alter HR compared to baseline (Figure S2a,c,e). As observed with vandetanib above, ΔHR was reduced over time in both the pazopanib and vehicle groups compared to baseline. This was particularly evident during the resting morning phase and this decrease was sustained throughout the 10‐day posttreatment period (Figure S2d). Pazopanib did not significantly alter HR or ΔHR compared to vehicle at any particular time point measured. However, integrated area under the curve analysis revealed significant trend differences between pazopanib and vehicle during the 24 hours, morning and evening measurements of ΔHR (Mann‐Whitney U test, *P* \< 0.05; Figure S2b,d,f).

The HR circadian oscillations measured during pazopanib dosing did not differ from vehicle or baseline for first 3 days of treatment (Figure S3a). However, during the 9th and 10th day of the posttreatment period significant tachycardia was found compared to vehicle (Figure S3b). Integrated area under the curve analysis also identified significant trend differences between pazopanib and vehicle throughout the last 2 days of dosing and the 10‐day posttreatment period (Mann‐Whitney U test, *P* \< 0.05; Figure S3B). This suggests that HR increases associated with pazopanib only occur post dosing.

### 3.2.2. Blood pressure {#prp2477-sec-0014}

Similar to vandetanib, 21 days of pazopanib dosing caused significant pressor effects, when observing ΔMAP, compared to the starting baseline values (Figure [6](#prp2477-fig-0006){ref-type="fig"}). However, these effects were not detected by MAP raw data (Figure [6](#prp2477-fig-0006){ref-type="fig"}A,C,E). Additionally, when compared to vandetanib treatment, the effects of pazopanib were slower in onset and of smaller magnitude (Figure [6](#prp2477-fig-0006){ref-type="fig"}B,D,F). Pazopanib induced significant increases in ΔMAP from the third day of pazopanib dosing, taking 2 days longer to peak compared to the vandetanib‐treated animals (Figure [6](#prp2477-fig-0006){ref-type="fig"}B,D,F vs Figure [2](#prp2477-fig-0002){ref-type="fig"}B,D,F). This persisted until the end of the experiment (Figure [6](#prp2477-fig-0006){ref-type="fig"}B). The effects of pazopanib on MAP during the rodent resting morning phase were variable and somewhat inconsistent (Figure [6](#prp2477-fig-0006){ref-type="fig"}D). However, during the active evening period, elevation in ΔMAP was more consistent and sustained throughout both the treatment period (21 days) and "off"‐treatment period (10 days) (Figure [6](#prp2477-fig-0006){ref-type="fig"}B,D,F).

![Mean arterial blood pressure (MAP) of rats dosed with pazopanib 30 mg/kg/day (n = 7) and vehicle (n = 4). A, MAP B, change in MAP compared to baseline (ΔMAP) measured for 24 hours, C, MAP and D, ΔMAP measured during the morning (06:00‐12:00), E, MAP and F, ΔMAP measured during the evening (18:00‐23:45). Data displayed as mean ± SEM. \**P* \< 0.05 comparing each time point to baseline; ^+^ *P* \< 0.05 comparing vehicle vs pazopanib at the same time point and ^\#^ *P* \< 0.05 comparing area over or under the curve of vehicle vs pazopanib](PRP2-7-e00477-g006){#prp2477-fig-0006}

Pazopanib significantly increased ΔSBP during the 24 hours and the active evening measurements (Figure [7](#prp2477-fig-0007){ref-type="fig"}). This was sustained throughout both the 21‐day dosing period and the 10‐day "off"‐treatment period (*P* \< 0.05; Figure [7](#prp2477-fig-0007){ref-type="fig"}B,F). However, raw SBP data did not show pazopanib induced changes (Figure [7](#prp2477-fig-0007){ref-type="fig"}A,C,E; Table S2). In addition, unlike vandetanib treatment, no changes in ΔSBP were observed in the morning resting phase with pazopanib treatment, compared to baseline. During the active evening phase, there were significant differences between pazopanib and vehicle groups on the 11th and 15th day of the dosing period and the 8th day of the posttreatment period (Figure [7](#prp2477-fig-0007){ref-type="fig"}F). Interestingly, integrated area under the curve analysis found trend differences in ΔSBP found between vehicle and pazopanib over the entire experiment, in the 24 hours, morning and evening (Mann‐Whitney U test, *P* \< 0.05; Figure [7](#prp2477-fig-0007){ref-type="fig"}B,D,F). Similar effects were observed on DBP and ΔDBP (Figure [8](#prp2477-fig-0008){ref-type="fig"}).

![Mean systolic pressure (SBP) of rats dosed with pazopanib 30 mg/kg/day (n = 7) and vehicle (n = 4). A, SBP and B, change in SBP compared to baseline (ΔSBP) measured for 24 hours, C, SBP and D, ΔSBP measured during the morning (06:00‐12:00), E, SBP and F, ΔSBP measured during the evening (18:00‐23:45). Data displayed as mean ± SEM. \**P* \< 0.05 comparing each time point to baseline; ^+^ *P* \< 0.05 comparing vehicle vs pazopanib at the same time point and ^\#^ *P* \< 0.05 comparing area over or under the curve of vehicle vs pazopanib](PRP2-7-e00477-g007){#prp2477-fig-0007}

![Mean diastolic pressure (DBP) of rats dosed with pazopanib 30 mg/kg/day (n = 7) and vehicle (n = 4). (A) DBP and (B) change in DBP compared to baseline (ΔDBP) measured for 24 hours, (C) DBP and (D) ΔDBP measured during the morning (06:00‐12:00), (E) DBP and (F) ΔDBP measured during the evening (18:00‐23:45). Data displayed as mean ± SEM. \**P* \< 0.05 comparing each time point to baseline; ^+^ *P* \< 0.05 comparing vehicle vs pazopanib at the same time point and ^\#^ *P* \< 0.05 comparing area over or under the curve of vehicle vs pazopanib](PRP2-7-e00477-g008){#prp2477-fig-0008}

In contrast to vandetanib, pazopanib did not significantly alter the circadian pattern of MAP, SBP, or DBP during the first 3 days of pazopanib dosing or the last 2 days of pazopanib dosing followed by a 10‐day "off"‐treatment period, compared to vehicle or baseline (Figure S3c‐h).

4. DISCUSSION {#prp2477-sec-0015}
=============

In the present study, we have demonstrated that, in rats instrumented for radiotelemetry recording of blood pressure and other cardiovascular variables over an extended period, hypertension can be induced by both vandetanib and pazopanib. These findings extend previous telemetry‐based studies in rats using related RTKI treatments.[21](#prp2477-bib-0021){ref-type="ref"}, [22](#prp2477-bib-0022){ref-type="ref"}, [23](#prp2477-bib-0023){ref-type="ref"}, [27](#prp2477-bib-0027){ref-type="ref"}, [28](#prp2477-bib-0028){ref-type="ref"} They are also consistent with the hypertensive effects of vandetanib and pazopanib that have been described in the clinical setting[18](#prp2477-bib-0018){ref-type="ref"}; Pinkas et al, 2017). Of particular note in this study, however, is the finding that after extended treatment with both RTKIs, which more closely reflects the clinical regimens, blood pressure remained consistently elevated, even after 8‐10 days following the cessation of treatment. In the case of vandetanib, this time scale is entirely consistent with Phase 1 clinical trials in man that have indicated that this drug is eliminated slowly from the body with a *t* ~1/2~ of *circa* 10 days.[29](#prp2477-bib-0029){ref-type="ref"} Pazopanib is excreted more quickly and the estimated *t* ~1/2~ in man is *circa* 30 h (Australian Public Assessment Report PM‐2009‐01084‐4).

The effects of vandetanib were most obvious in terms of elevation in SBP, however, there was also an elevation in DBP, particularly throughout the treatment period. Compared to vandetanib, the increase in blood pressure with pazopanib was slower in onset and smaller in magnitude. The elevation in overall pressure is consistent with our previous studies using these RTKIs in the Doppler flowmetry model, wherein we showed significant increases in MAP with both vandetanib and pazopanib that were associated with vasoconstrictions in the mesenteric and hindquarters vascular beds.[20](#prp2477-bib-0020){ref-type="ref"} While DBP was not directly measured in these earlier studies, it would be expected that changes in peripheral vascular resistance would strongly affect DBP.[30](#prp2477-bib-0030){ref-type="ref"} In the present study, it would appear that these RTKIs have directly affected SBP to a greater extent than DBP, likely via mechanisms involving changes in stroke volume and contractility. However, further studies are clearly needed to better understand the effects of RTKIs on DBP and SBP.

It is notable that pazopanib is much more potent as an inhibitor of VEGFR2‐mediated signaling or binding than vandetanib.[5](#prp2477-bib-0005){ref-type="ref"}, [6](#prp2477-bib-0006){ref-type="ref"} It is therefore possible that other kinases (other than VEGFR2) may additionally contribute to larger effects of vandetanib on MAP and SBP observed here. These might include RTKs such as EGFR and PDGFR which have higher affinity for vandetanib.[6](#prp2477-bib-0006){ref-type="ref"}

This study is the first to monitor the longer‐term, continuous impact of vandetanib and pazopanib on the cardiovascular system. Similar or related RTKIs such as cediranib,[31](#prp2477-bib-0031){ref-type="ref"} sorafenib,[20](#prp2477-bib-0020){ref-type="ref"}, [21](#prp2477-bib-0021){ref-type="ref"} and sunitinib[28](#prp2477-bib-0028){ref-type="ref"}, [32](#prp2477-bib-0032){ref-type="ref"} have been investigated in other studies where the cardiovascular effects of these compounds were monitored over periods of between 4 days and 4 weeks (continuous) treatment, and showed that MAP returns quickly to baseline levels following the end of treatment. Indeed, Blasi et al[32](#prp2477-bib-0032){ref-type="ref"} noted that the pressor effects of sunitinib diminished even during the last few days of treatment. Moreover, no associated changes in cardiac structure or function were observed.[32](#prp2477-bib-0032){ref-type="ref"}

Observation of the circadian changes in cardiovascular variables revealed that HR, MAP, SBP, and DBP all peaked during the rodent active evening phase and reached lower levels during the rodent resting phase. During the vandetanib dosing period, the oscillations in MAP, SBP, and DBP were disrupted and clear elevations in all three pressure responses were observed. However, during vandetanib treatment the circadian rhythm observed in HR was much better maintained. In contrast, following pazopanib treatment, the periodic circadian variations in all four cardiovascular variables were well maintained. These changes point to multiple factors contributing to the larger and more disruptive changes in diurnal variations in blood pressure observed with vandetanib (relative to pazopanib).

Although the very slow elimination and clearance of vandetanib from the body[29](#prp2477-bib-0029){ref-type="ref"} is likely to contribute to the maintained increased in blood pressure observed in the present study during the 10‐day "off"‐treatment period, it is also likely that other hemodynamic compensatory mechanisms are contributing to this sustained effect. For example, the diurnal variation in HR is maintained well in the presence of both drugs, although in the case of vandetanib, drug treatment leads to a small bradycardia and a reduction in the peak‐trough amplitudes. During vandetanib treatment, however, maintenance of a regular diurnal change in, particularly, SBP took longer to reestablish after the initial pressure response. It is possible, therefore, that some resetting of the blood pressure occurs during this period. In the case of pazopanib, there are parallel changes in both DBP (elevation) and HR during the drug washout phase that might also point to compensatory changes, particularly since these both appear to result from an extended period of peak blood pressure and HR during the rodent active period.

The mechanisms underlying the hypertensive effects of anti‐VEGF therapies has yet to be fully elucidated, although a reduction in VEGF‐induced nitric oxide (NO) production has been heavily implicated.[33](#prp2477-bib-0033){ref-type="ref"}, [34](#prp2477-bib-0034){ref-type="ref"} Under normal physiological conditions, VEGF signaling enhances endothelial‐derived NO production; this vasoactive substance is subsequently available to act on vascular smooth muscle, evoking a vasodilatation and reducing overall peripheral vascular resistance.[33](#prp2477-bib-0033){ref-type="ref"} Interference with the VEGF signaling cascade decreases the availability of NO, and is associated with vasoconstriction, capillary rarefaction, and consequently hypertension.[33](#prp2477-bib-0033){ref-type="ref"}, [34](#prp2477-bib-0034){ref-type="ref"} To date, the pathophysiology of RTKI‐induced hypertension, particularly relating to inhibition of VEGF, is poorly defined. There is some evidence to suggest that concomitant treatment with antihypertensive agents targeting the renin‐angiotensin‐aldosterone system, or calcium signaling pathways, may improve progression‐free survival and overall survival in cancer patients (reviewed by reference.[34](#prp2477-bib-0034){ref-type="ref"} Moreover, in vitro data suggest that nitrates and beta‐blockers may also be associated with cancer regression. However, until we fully understand the pathways and mechanisms underlying the cardiovascular effects of VEGF which are essential for normal function, future developments in the therapeutic area will remain a challenge.

It is widely acknowledged that VEGF and its receptors are expressed in a variety of tissues under normal physiological conditions.[35](#prp2477-bib-0035){ref-type="ref"}, [36](#prp2477-bib-0036){ref-type="ref"}, [37](#prp2477-bib-0037){ref-type="ref"}, [38](#prp2477-bib-0038){ref-type="ref"} During development,[39](#prp2477-bib-0039){ref-type="ref"}, [40](#prp2477-bib-0040){ref-type="ref"} wound healing[41](#prp2477-bib-0041){ref-type="ref"} and the luteal phase of the menstrual cycle,[42](#prp2477-bib-0042){ref-type="ref"} VEGF expression is high. However, its role in the quiescent vasculature has yet to be fully determined and until recently it was believed that VEGF played an insignificant role in the established adult vasculature.

However, there is increasing evidence demonstrating the important role of VEGF in survival of not only angiogenic vessels, but normal, established vasculature as well.[12](#prp2477-bib-0012){ref-type="ref"}, [35](#prp2477-bib-0035){ref-type="ref"}, [43](#prp2477-bib-0043){ref-type="ref"}, [44](#prp2477-bib-0044){ref-type="ref"} Thus, prolonged anti‐VEGF therapy is associated with the concept of rarefaction, "normalisation" of the vasculature[43](#prp2477-bib-0043){ref-type="ref"} and remodeling of these newly formed microvessels. This leads to a loss of structural pericyte coverage, and in many cases actual regression of the blood vessels.[12](#prp2477-bib-0012){ref-type="ref"}, [35](#prp2477-bib-0035){ref-type="ref"}, [43](#prp2477-bib-0043){ref-type="ref"} More recently, it has also been suggested that VEGF plays a similar role in maintaining the function of normal well‐established microvessels.[35](#prp2477-bib-0035){ref-type="ref"} If so, this may explain the hypertension observed in patients following RTKI treatment, since this will naturally lead to an increase in overall total peripheral resistance.[20](#prp2477-bib-0020){ref-type="ref"}, [44](#prp2477-bib-0044){ref-type="ref"} If this hypertension is indeed based on structural changes in the vasculature, then this could well contribute to the sustained hypertension observed in the present study during the "off"‐drug period, particularly following vandetanib treatment.

In summary, the present study has demonstrated that the hypertension associated with RTKI treatment can be recapitulated in a conscious rat model and that this cardiovascular effect is substantially maintained during a prolonged "off"‐treatment period. The reasons for this remain to be established, but further work on the potential changes in microvessel structure and the role of local vasoactive substances (eg, NO) should begin to provide important insights into the mechanisms underlying this serious side effect. This is particularly relevant to the clinical situation where antiangiogenic adjunct therapies are being extended from patients with late‐stage cancer to younger patients at an earlier stage of disease progression.
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